BioCorRx Inc. in brief
BioCorRx Inc. is a listed company in the Medical Care Facilities industry, based in Anaheim, California, USA. Its last known market value was $18 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $1 M and a net loss of $3 M.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About BioCorRx Inc.
We were incorporated as Cetrone Energy Company on January 28, 2008 in the State of Nevada. From inception until we completed our reverse acquisition of Fresh Start Private, Inc., the principal business of the Company originally was to develop “green” renewable fuel sources for agricultural operations, specifically biodiesel. On July 26, 2010, we filed an amendment to our articles of incorporation changing our name to Fresh Start Private Management, Inc. During that time, we had no revenue and our operations were limited to capital formation, organization, and development of our business plan and target customer market. As a result of the reverse acquisition of FSP, on October 31, 2011, we ceased our prior operations and we are now a holding company and our wholly owned subsidiary engages in alcoholism and opioid addiction treatment through our BioCorRx® Recovery Program and related products.
From the company's annual report filed with the US SEC: read the report
BioCorRx Inc. timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed Fresh Start Private Management, Inc.Formerly Cetrone Energy CO.
- 2014
- ✎Renamed BioCorRx Inc.Formerly Fresh Start Private Management, Inc..
- 2025
- 💰Record revenue of $1 millionFY2025, the highest of the 8 years on record.
Events of BioCorRx Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,559 (Jan 2020) · #4,664 (Jan 2021) · #5,258 (Jan 2022) · #5,721 (Dec 2022) · #5,223 (Jul 2023)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -430.0%
- Operating margin
- -603.8%
- Return on equity
- —
- Liabilities / assets
- 635.8%
- Net debt
- $-0M
- Revenue growth
- +7900.0%
- R&D / revenue
- 221.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +7900.0% | $-5M | $-3M | -430.0% |
| Dec 2024 | $0M | -88.9% | $-5M | $-5M | -51100.0% |
| Dec 2023 | $0M | -57.1% | $-4M | $-4M | -4188.9% |
| Dec 2022 | $0M | +320.0% | $-5M | $-4M | -2085.7% |
| Dec 2021 | $0M | -58.3% | $-6M | $-5M | -10420.0% |
| Dec 2020 | $0M | -50.0% | $-7M | $-4M | -2925.0% |
| Dec 2019 | $0M | -36.8% | $-6M | $-6M | -2520.8% |
| Dec 2018 | $0M | — | $-5M | $-7M | -1731.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-2M | — | — | $-0.19 | — |
| Dec 2024 | $-1M | — | — | $-0.49 | — |
| Dec 2023 | $-2M | — | — | — | — |
| Dec 2022 | $-2M | $0M | $-2M | — | — |
| Dec 2021 | $-4M | $0M | $-4M | $-0.81 | — |
| Dec 2020 | $-2M | $0M | $-2M | $-0.65 | — |
| Dec 2019 | $-3M | $-0M | $-3M | $-1.71 | — |
| Dec 2018 | $-2M | $0M | $-2M | $-2.60 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 16, 202610-QQuarterly report · period to Sep 2026
- Sep 4, 20268-KCurrent reportDirectors or officers changed
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- May 15, 202610-QQuarterly report · period to Mar 2026
- Apr 2, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Nov 14, 202510-QQuarterly report · period to Sep 2025
- Aug 14, 202510-QQuarterly report · period to Jun 2025
- Aug 1, 20258-KCurrent reportMaterial agreement · Unregistered share sale
- May 15, 202510-QQuarterly report · period to Mar 2025
- Mar 31, 202510-KAnnual report · period to Dec 2024
- Mar 11, 20258-KCurrent reportMaterial agreement · Unregistered share sale · Other events
Official filings of BioCorRx Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-5 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $2 M
- Total liabilities
- $14 M
- Total equity
- $-11 M
As of December-2025
Insider trading at BioCorRx Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lourdes FelixCEO and CFO, Director | Grant or award | +13,158 | — | — | 843,578 | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +43,860 | — | — | 2.50 M | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +13,158 | — | — | 2.51 M | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +55,494 | — | — | 2.45 M | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +55,556 | — | — | 2.40 M | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +1.11 M | — | — | 2.34 M | Form 4 |
| filed | Lourdes FelixCEO and CFO, Director | Grant or award | +15,625 | — | — | 830,420 | Form 4 |
| filed | Louis C. LucidoPresident, Director, 10% owner | Grant or award | +52,085 | — | — | 1.22 M | Form 4 |
BioCorRx Inc. scorecard#
Passes 1 of the 9 checks that could be worked out: strongest in growth (1 of 3), weakest in financial health (0 of 3). Fiscal year 2025.
Valuationnot known
Growth1 of 3
Profitability0 of 2
Financial health0 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Medical Care Facilities, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
BioCorRx Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 797 | 7.7 | 89 | 214 | 48 | 123 | 240 | 377 | 657 | 702 | |
| Cost of revenue | — | 1.7 | 36 | 15r | 5.9 | 96 | 82 | 171 | 324 | 175 | |
| Research and development | 1,769 | 1,483 | 891 | 1,459 | 1,606 | 4,274 | 1,125 | 152 | 451 | — | |
| Selling, general and administrative | 3,794 | 3,612 | 2,875 | 3,410 | 3,741 | — | — | — | — | — | |
| General and administrative | — | — | — | — | 3,741 | 3,168 | 4,565 | 4,423 | 2,740 | 2,545 | |
| Operating expenses | 5,629 | 5,130 | 3,877 | 4,912 | 5,558 | 7,615 | 5,802 | 5,003 | 3,548 | 2,884 | |
| Operating income | −4,832 | −5,123 | −3,788 | −4,698 | −5,510 | −7,492 | −5,561 | −4,626 | −2,891 | −2,182 | |
| Interest expense and finance costs | 224 | 777 | 194 | 151 | 19 | 511 | 1,622r | −1,959r | 11,149 | 1,048 | |
| Net interest income | — | — | — | — | −566 | −511 | — | — | — | — | |
| Non-interest income | — | 106 | 3.6 | 7.4 | 2.4 | 34 | — | — | — | — | |
| Other non-operating income (expense) | 1,323 | −90 | 17 | 321 | 299 | 3,985 | −487 | −1,958 | −26,815 | −3,722 | |
| Income before tax | −3,509 | −5,212 | −3,770 | −4,377 | −5,211 | — | — | — | — | — | |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | |
| Net income including minority interests | −3,509 | −5,212 | −3,770 | −4,377r | 5,211 | — | — | — | — | — | |
| Minority interests' share of net income | −69 | −106 | — | — | −5,278 | −3,472 | −6,040 | −6,512 | −29,706 | — | |
| Net income attributable to shareholders | −3,440 | −5,106r | −3,770 | −4,377 | −5,211 | −3,507 | −6,048 | −6,584 | −29,706 | −5,904 | |
| Earnings per share, basic | — | — | — | — | -0.81 | -0.65 | -1.71 | -2.60 | -12.77r | -0.03 | |
| Earnings per share, diluted | -0.19 | -0.49 | — | — | -0.81 | -0.65 | -1.71 | -2.60 | -12.77r | -0.03 | |
| Shares, weighted average (diluted) | 18 | 10r | 2.7 | 1.4 | 1.1 | 1.1 | 1.1 | 2.4r | 1.8r | 250 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 139 | 88 | 65 | 69 | 86 | 592 | 2,646 | 280 | 11 | 92 | |
| Receivables | 253 | 0 | 0.7 | 35 | — | — | — | — | — | — | |
| Inventory | 143 | 0 | — | — | — | — | — | — | — | — | |
| Current assets | 814 | 118 | 187 | 317 | 228 | 975 | 3,047 | 319 | 55 | 101 | |
| Property, plant and equipment | 4.1 | 19 | 51 | 77 | 103 | 129 | 148 | 44 | 19 | 22 | |
| Right-of-use (leased) assets | 159 | 199 | 97 | 270 | 385 | 490 | 459 | — | — | — | |
| Goodwill | 563 | 0 | — | — | — | — | — | — | — | — | |
| Other intangible assets | 564 | 7.8 | 9.0 | 10 | 0 | 177 | 224 | — | 252 | — | |
| Long-term investments | — | — | — | 45 | 45 | 45 | 42 | 13 | 13 | 18 | |
| Total assets | 2,147 | 386 | 389 | 767 | 820 | 1,827 | 3,933 | 628 | 339 | 470 | |
| Accounts payable | 4,029 | 3,024 | 2,473 | 2,013 | 1,777r | 1,181 | 709 | 656r | 715 | 768r | |
| Current liabilities | 8,306 | 8,208 | 6,431 | 5,364 | 4,386 | 3,052 | 2,551 | 6,127 | 1,638 | 2,451 | |
| Lease liabilities (non-current) | 116 | 159 | 11 | 181 | 316 | 435 | 428 | — | — | — | |
| Total liabilities | 13,674 | 12,741 | 10,341 | 8,968 | 7,781 | 6,037 | 4,992 | 6,335 | 4,232 | 8,601 | |
| Retained earnings | −86,649 | −83,209 | −78,103 | −74,336 | −69,967 | −64,688 | −61,216r | −55,176 | −48,841 | −19,135 | |
| Shareholders' equity | −11,224 | −12,120 | −9,824 | −8,076r | −6,961r | −4,210r | −1,059r | −5,706 | −3,893 | −8,130 | |
| Minority interests | −303 | −235 | −129 | −125 | −118 | −115 | −81r | −72 | — | — | |
| Total equity | −11,527 | −12,355 | −9,953r | −8,202 | −6,961 | −4,210r | −1,059r | −5,634 | −3,893 | — | |
| Total liabilities and equity | 2,147 | 386 | 389 | 767 | 820 | 1,827 | 3,933 | 628 | 339 | 470 | |
| Shares outstanding | 24 | 13 | 8.7 | 7.7 | 6.7 | 5.5 | 5.3 | 2.6 | 2.4r | 182 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 44 | 33 | 27 | 27 | 64 | 77 | 29 | 7.4 | 34 | 30 | |
| Share-based compensation | 593 | 1,219r | 277 | 355 | 210 | 355 | 1,966 | 2,807 | 831 | 582r | |
| Cash from operating activities | −2,298 | −1,096 | −1,853 | −2,042 | −3,538 | −2,152 | −2,937 | −1,826 | −2,540 | −1,999r | |
| Capital expenditure | — | — | — | 0 | −2.0r | 0 | −123 | −10 | −3.0 | −306 | |
| Intangible assets bought | — | — | — | 0 | −48 | — | — | −15 | — | — | |
| Cash from investing activities | — | — | — | 0 | −50 | −9.2 | −122 | −56 | −3.0 | −328r | |
| Shares issued | — | 700 | — | 1,250 | 2,250 | 0 | 100 | 1,400 | 940 | 100 | |
| Cash from financing activities | 2,350 | 1,119 | 1,850 | 2,025 | 3,081 | 107 | 5,425 | 2,150 | 2,412 | 2,250r | |
| Change in cash | — | — | — | — | −506 | −2,054 | 2,366 | 268 | −131 | −78r | |
| Report | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Jun 30, 2026
Events at BioCorRx Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 2 · Directors and officers 6 · Material agreement 9 · Unregistered share sale 6
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K |
As of Sep 4, 2026
How BioCorRx Inc. compares in Medical Care Facilities
- Revenue$1 M · higher than 1% of 133
- Net margin-400.0% · higher than 1% of 127
Peer comparison · Medical Care Facilities
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BioCorRx Inc.🇺🇸 | $18 M | — | -400.0% | — |
| HCA Healthcare, Inc.🇺🇸 | $96.8 B | 14.3× | 8.6% | +7.1% |
| Fresenius SE & Co. KGaA🇩🇪 | $30.7 B | 20.4× | 5.5% | -3.4% |
| Dr. Sulaiman Al Habib Medical Services Group Company🇸🇦 | $22.2 B | 34.6× | 17.5% | +9.6% |
| Tenet Healthcare Corporation🇺🇸 | $21.4 B | 5.6× | 17.2% | +3.1% |
| IHH Healthcare Berhad🇲🇾 | $18.1 B | 34.8× | 8.2% | — |
| JD Health International Inc.🇨🇳 | $15.7 B | 20.2× | 7.3% | — |
| Apollo Hospitals Enterprise Limited🇮🇳 | $14.3 B | 68.1× | 7.8% | — |
| Fresenius Medical Care AG🇩🇪 | $12.4 B | 11.3× | 5.0% | +5.8% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
How current the figures are
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BioCorRx Inc.? Verify and update this profile — free
Show BioCorRx Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.